Free Trial
NASDAQ:GNLX

Genelux 8/14/2024 Earnings Report

Genelux logo
$3.78 +0.34 (+9.88%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$3.78 +0.01 (+0.13%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Genelux Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genelux Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Genelux's next earnings date is estimated for Thursday, November 13, 2025, based on past reporting schedules.

Conference Call Resources

Genelux Earnings Headlines

Brookline Capital Management Estimates Genelux Q3 Earnings
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
See More Genelux Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genelux? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genelux and other key companies, straight to your email.

About Genelux

Genelux (NASDAQ:GNLX), a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

View Genelux Profile

More Earnings Resources from MarketBeat